Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen Day

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The New York Times on the Web|May 8, 1996
Genetics research begets questions: biotech industry seeks ethics advice to deal with complex issuesKathleen Day
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|August 19, 2007
Evaluation of expectations and knowledge in bariatric surgery patientsAndrea Bauchowitz, Leila Azarbad, Kathleen Day, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 31, 2016
Feedback to Supervisors: Is Anonymity Really So Important?Nancy L Dudek, Suzan Dojeiji, Kathleen Day, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 27, 2021
Progression Toward a Competency-Based Assessment ParadigmKatherine Berg, Anita Wilson, Kathleen Day, et al.
Headache|October 21, 2018
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 StudiesNoah Rosen, Eric Pearlman, Dustin Ruff, et al.
Headache|April 12, 2019
Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic MigraineNoah Rosen, Eric Pearlman, Dustin Ruff, et al.
The British Journal of Developmental Psychology|November 18, 2025
Playing the part: Children's willingness and embarrassment to play gender stereotype-violating rolesElizabeth J Parks-Stamm, Clarissa Leuthold, Carolin Schuster, et al.
Journal of Managed Care & Specialty Pharmacy|April 22, 2022
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)Anna Ambrosini, Emad Estemalik, Julio Pascual, et al.
Journal of Psychopharmacology (Oxford, England)|March 24, 2016
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patientsChris Bushe, Kathleen Day, Victoria Reed, et al.
The Journal of Headache and Pain|February 7, 2021
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMichael Ament, Kathleen Day, Virginia L Stauffer, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The New York Times on the Web|May 8, 1996
Genetics research begets questions: biotech industry seeks ethics advice to deal with complex issuesKathleen Day
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|August 19, 2007
Evaluation of expectations and knowledge in bariatric surgery patientsAndrea Bauchowitz, Leila Azarbad, Kathleen Day, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|March 31, 2016
Feedback to Supervisors: Is Anonymity Really So Important?Nancy L Dudek, Suzan Dojeiji, Kathleen Day, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 27, 2021
Progression Toward a Competency-Based Assessment ParadigmKatherine Berg, Anita Wilson, Kathleen Day, et al.
Headache|October 21, 2018
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 StudiesNoah Rosen, Eric Pearlman, Dustin Ruff, et al.
Headache|April 12, 2019
Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic MigraineNoah Rosen, Eric Pearlman, Dustin Ruff, et al.
The British Journal of Developmental Psychology|November 18, 2025
Playing the part: Children's willingness and embarrassment to play gender stereotype-violating rolesElizabeth J Parks-Stamm, Clarissa Leuthold, Carolin Schuster, et al.
Journal of Managed Care & Specialty Pharmacy|April 22, 2022
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)Anna Ambrosini, Emad Estemalik, Julio Pascual, et al.
Journal of Psychopharmacology (Oxford, England)|March 24, 2016
A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patientsChris Bushe, Kathleen Day, Victoria Reed, et al.
The Journal of Headache and Pain|February 7, 2021
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMichael Ament, Kathleen Day, Virginia L Stauffer, et al.
Pageof 2